Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Niraparib for HER2-negative, germline BRCA mutated, locally advanced or metastatic breast cancer – first or second line. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2014 Indexing Status Subject indexing assigned by CRD MeSH Breast Neoplasms; Poly(ADP-ribose) Polymerasess Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Centre, School of Health&Population Sciences, University of Birmingham, Public Health building, Edgbaston, Birmingham, B15 2TT. Tel: +44 121 414 7831 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32014001141 Date abstract record published 22/10/2014 |